Metronomic Capecitabine Plus Aromatase Inhibitor as Initial Therapy in Patients With Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer: The Phase III MECCA Trial
Ruoxi Hong(Sun Yat-sen University), Shusen Wang(Sun Yat-sen University), Qiufan Zheng(Sun Yat-sen University), Yanxia Shi(Sun Yat-sen University), Ying Lin(Sun Yat-sen University), Fei Xu(Sun Yat-sen University), Jingmin Zhang, Xin An(Sun Yat-sen University), Xinlan Liu(Yunnan Agricultural University), Kuikui Jiang(Sun Yat-sen University), Meiting Chen(Sun Yat-sen University), Cong Xue, Zhen Dai(Chengdu Center for Disease Control and Prevention), Dongshao Chen(Sun Yat-sen University), Herui Yao(Sun Yat-sen University), Jiajia Huang(Sun Yat-sen University), Hui Li(First Affiliated Hospital of Zhengzhou University), Quchang Ouyang(Hunan Cancer Hospital), Yue-E Teng(First Hospital of China Medical University), Guorong Zou(Panyu District Central Hospital), Qianjun Chen(Guangzhou University of Chinese Medicine), Heng Huang(Qujiang People's Hospital), Xinhong Wu(Jiangnan University), Xi-Wen Bi(Sun Yat-sen University), Zhongyu Yuan(Sun Yat-sen University)
Cited by 12
Related Papers
LNMAT1 promotes lymphatic metastasis of bladder cancer via CCL2 dependent macrophage recruitment
|Nature Communications|2018|525
Induction of Pyroptosis and Its Implications in Cancer Management
|Frontiers in Oncology|2019|274
Blocking the recruitment of naive CD4+ T cells reverses immunosuppression in breast cancer
|Cell Research|2017|225
Camrelizumab Plus Apatinib in Patients With Advanced Cervical Cancer (CLAP): A Multicenter, Open-Label, Single-Arm, Phase II Trial
|Journal of Clinical Oncology|2020|217